GET DAILY SIGNALSDirexion Daily Healthcare Bull 3X Shares (CURE) Delivers +34% Gain Amid Healthcare Rally
Key Takeaways
- CURE climbed roughly 34% over the last 30 days, advancing from about $131.19 to $175.99 as healthcare equities rallied and the fund's leverage amplified the move.
- Over the last quarter the fund posted a similar gain of about 34%, but the path was volatile: it reached the mid-$140s in mid-August, pulled back near $122 in early September, and then surged from late October onward.
- CURE is a 3x leveraged ETF that seeks triple the daily return of the Health Care Select Sector Index, magnifying both gains and losses on a daily-reset basis.
- The strongest upside came in late October and early November, punctuated by elevated intraday swings and heavier trading volume that reflect the fund's leverage.
- Because CURE rebalances daily, its longer-term returns can diverge materially from three times the index's cumulative performance, making it best suited for short-term trading horizons.
- For additional detail, explore CURE's Price Targets, Earnings, and Forecast pages.
- Explore Trending AI Robots to review curated, top-performing AI trading bots across thousands of tickers.
Understanding CURE and Its Market Role
CURE is an exchange-traded fund issued by Direxion that seeks daily investment results equal to 300% of the daily performance of the Health Care Select Sector Index. The underlying index is composed of large-cap U.S. healthcare companies drawn from the S&P 500, spanning pharmaceuticals, biotechnology, healthcare equipment and services, and managed care. Investors follow CURE primarily as a tactical vehicle to express short-term bullish views on the healthcare sector with amplified exposure. Its 3x leverage makes it substantially more volatile than non-leveraged sector funds such as the XLV Health Care Select Sector SPDR Fund, and it is generally intended for active traders rather than long-term buy-and-hold investors. I also checked this using Tickeron’s AI Screener to see how the fund compares to others in the industry.
Performance Snapshot: 30 Days and the Recent Quarter
Over the last 30 days, CURE advanced from a closing price of $131.19 to $175.99, a gain of about 34%. The rally was not linear; the fund consolidated in the low $130s in mid-October before accelerating in the final weeks of the period.
The last quarter tells a similar but more volatile story. Measured from mid-August, when the fund closed near $131, CURE is up roughly 34% over three months. However, that headline figure masks significant swings: the fund climbed toward the mid-$140s in mid-August, fell back to the low $120s in early September, traded sideways through most of the fall, and then broke sharply higher in late October and early November. On balance, the fund's gains over the last 30 days account for essentially all of its quarterly advance.
Drivers Behind the Recent 30-Day Advance
The dominant driver of CURE's move is mechanical: the fund seeks 300% of the daily return of the Health Care Select Sector Index, so any rally in large-cap healthcare stocks is roughly tripled on a day-to-day basis. During the last 30 days, the underlying healthcare index posted sustained gains, and CURE's leverage translated that strength into an outsized advance of about 34%.
The rally was accompanied by a clear shift in trading activity. Volume expanded notably in late October and early November, and daily ranges widened as the fund moved from the $130s into the $170s. A particularly sharp session around early November, when the fund traded through a wide intraday range before finishing lower, illustrates the heightened volatility that leverage can produce even amid an overall uptrend. Risk appetite across the broader market and rotation into defensive-growth sectors, including healthcare, provided additional tailwinds, but the fund's amplified structure remains the primary explanation for the magnitude of the move.
Quarterly Path: Volatility and Re-Acceleration
The quarterly narrative is one of recovery and re-acceleration rather than a straight line higher. After peaking in the mid-$140s in mid-August, CURE gave back much of that advance through early September, sliding near $122 as the healthcare complex cooled and the leveraged structure amplified the pullback. The fund then spent several weeks in a relatively narrow range before momentum returned in the second half of October.
From late October through early November, renewed strength in large-cap healthcare names—supported by steady investor demand for the sector and a generally constructive market backdrop—pushed the underlying index higher, and CURE's 3x exposure converted that into a rapid ascent. The result is a three-month gain of about 34%, with nearly all of the appreciation concentrated in the most recent weeks.
Key Factors to Watch Going Forward
Because CURE's returns are tied to the daily performance of the Health Care Select Sector Index, the most important factor to monitor is the direction and volatility of large-cap healthcare stocks. Sustained sector strength would tend to support the fund, while even modest pullbacks can be amplified roughly threefold on a daily basis. From what I see, investors should also watch broader market risk appetite, interest-rate expectations, and any sector-specific developments in pharmaceuticals, biotechnology, and managed care that could move the underlying index. Given the fund's daily rebalancing, tracking error and the compounding effects of volatile, choppy markets are meaningful considerations for anyone holding CURE beyond a single session. Monitoring volume and intraday volatility can help gauge whether momentum is expanding or fading. This information is provided for general purposes and should not be interpreted as a forecast or recommendation.
AI Tools I Rely On for Leveraged ETF Insights
When analyzing instruments like CURE, I find it helpful to review how AI-driven strategies interpret momentum and volatility. Tickeron's Trending AI Robots page offers a curated selection of top-performing bots from a much larger universe. These bots cover thousands of tickers with varying approaches and timeframes, which can provide useful context for traders focused on leveraged products. I typically spend a few minutes on the page to compare methodologies before forming a fuller view of recent market behavior.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CURE's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for CURE turned positive on October 09, 2026. Looking at past instances where CURE's MACD turned positive, the stock continued to rise in 42 of 46 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on CURE as a result. In 85 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 89%.
CURE moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for CURE crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 85%.
Following a +6.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where CURE advanced for three days, in 288 of 320 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
The Aroon Indicator entered an Uptrend today. In 230 of 247 cases where CURE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
Bearish Trend Analysis
The 10-day RSI Indicator for CURE moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 28 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CURE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
CURE broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
Advertisement